Clinical Trial Update: Study to Investigate the Efficacy and Safety of QGE031 in Adolescent Patients With Chronic Spontaneous Urticaria (CSU) [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluated the efficacy and safety of QGE031 (ligelizumab) in adolescent patients with chronic spontaneous urticaria; the study is completed with…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spontaneous Urticaria

Drugs mentioned

• QGE031 (Ligelizumab) (ligelizumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Chronic Spontaneous Urticaria | Phase 2 | Status: COMPLETED | Results posted: 2021-08-24